Ortho-Clinical Kills License Agreement For SynX Alzheimer’s Dx Technology
Ortho-Clinical Diagnostics has ended an exclusive agreement to license certain Alzheimer’s diagnostics technology from SynX Pharma, and has stopped trying to develop the technology, SynX said last week.
As a result, SynX has re-acquired from Ortho the worldwide rights to the technology.
SynX won a US patent for the technology in September 2002, and licensed it exclusively to Ortho one month later. SynX said it plans to “pick up where Ortho has left off” and continue developing the Alzheimer’s technology. The company will begin seeking non-exclusive licensing partners and consider plans to add it to its Nexus Dx point-of-care product line.
Agilent Technologies Consolidates RNA, Proteomics, Reagents Units
Agilent Technologies has consolidated its gene-expression, proteomics, and reagents businesses into a single corporate division, its gene-expression, proteomics, and reagents businesses, the company said last week.
The newly formed Integrated Biology Solutions unit will reside within Agilent’s Life Sciences and Chemical Analysis business group. Fran DiNuzzo, vice president of the bio-reagents, consumables, and services, will oversee the new division, Agilent said.
The unit, modeled on the systems biology approach, will “provide a single interface through which Agilent can better serve its customers in basic research, drug discovery and early-stage drug development,” said DiNuzzo, whose new title is vice president and general manager of IBS.
He also said the division will “enable” Agilent to better develop new products “that bridge multiple disciplines.”
Christina Maehr, a spokeswoman for Agilent, told GenomeWeb News, SNPtech Pharmacogenomics Reporter’s sister publication, that the company has no current plans to eliminate any positions. “This move is not an attempt to cut back” on spending, she said. Additionally, she said the company is “hiring for several positions,” including industry marketing manager.
Tm Bioscience Reports Increased Revenue, Losses for Year 2003
Tm Bioscience last week reported increased revenue and widening net losses in 2003.
Total revenues for the 12-month period ended Dec. 31, 2003, were $1.2 million, compared with $25,500 in 2002.
Meantime, 2003 R&D expenses rose to $3 million from $2.5 million in 2002. Net losses were $7.8 million, or $.06 per share, compared with $5.5 million, or $.05 per share, in 2002.
As of Dec. 31, 2003, Tm Bioscience had $2.7 million in cash and cash equivalents. Tm Bioscience did not report revenues by quarter until the third quarter of 2003.
Gene Logic Creates Subsidiary in the UK to Promote Business in Europe
Gene Logic has established a wholly owned subsidiary in the United Kingdom, the company said this week.
Starting this month, the new operation will help facilitate sales, marketing, and customer support in Europe. It has already hired an executive director for business development and will add additional personnel over the coming months.
Novartis’ Genomics Foundation Buys a Human cDNA Collection from OriGene
The Genomics Institute of the Novartis Research Foundation has purchased a human cDNA clone collection from OriGene Technologies, OriGene said this week.
The library contains more than 20,000 non-redundant full-length human cDNA clones, covering 65 to 80 percent of all predicted human cDNAs, according to the Rockville, Md.-based company. GNF will use the collection for in-house high-throughput research.
CombiMatrix Wins $5.9M Contract from Department of Defense
Acacia Research unit CombiMatrix has won a $5.9 million, two-year contract from the Department of Defense to develop microarray technology for the detection of biological weapons, the company said today.
Terms of the contract, which follows earlier funding from the DoD, call for CombiMatrix to develop an automated system that can detect potential biothreats, such as Bacillus anthracis and Yersinia pestis.
CombiMatrix has already been collaborating with the US Army Medial Research Institute of Infectious Disease since last year, under a Cooperative Research and Development Agreement, to integrate its technology into devices.